VanEck Biotech ETF (BBH)
- Previous Close
157.33 - Open
156.77 - Bid 154.00 x 200
- Ask 155.34 x 200
- Day's Range
153.47 - 156.77 - 52 Week Range
142.51 - 171.05 - Volume
53,720 - Avg. Volume
7,151 - Net Assets 452.51M
- NAV 157.49
- PE Ratio (TTM) 15.67
- Yield 0.43%
- YTD Daily Total Return -4.83%
- Beta (5Y Monthly) 0.85
- Expense Ratio (net) 0.35%
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
VanEck
Fund Family
Health
Fund Category
452.51M
Net Assets
2011-12-20
Inception Date
Performance Overview: BBH
Trailing returns as of 4/24/2024. Category is Health.
People Also Watch
Holdings: BBH
Top 10 Holdings (68.04% of Total Assets)
Sector Weightings
Recent News: BBH
Research Reports: BBH
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetRMBS: Lowering target price to $59.00
RAMBUS INC has an Investment Rating of HOLD; a target price of $59.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetVRSN: Raising target price to $201.00
VERISIGN INC has an Investment Rating of HOLD; a target price of $201.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetAnalyst Report: Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
RatingPrice Target